Pawar Vishakha Anand, Tyagi Anuradha, Verma Chaitenya, Sharma Kanti Prakash, Ansari Sekhu, Mani Indra, Srivastva Shailesh Kumar, Shukla Pradeep Kumar, Kumar Antresh, Kumar Vinay
The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.
Department of cBRN, Institute of Nuclear Medicine and Allied Science Delhi 110054, India.
Am J Transl Res. 2023 Aug 15;15(8):4984-5006. eCollection 2023.
Drug repurposing, also known as drug repositioning, entails the application of pre-approved or formerly assessed drugs having potentially functional therapeutic amalgams for curing various disorders or disease conditions distinctive from their original remedial indication. It has surfaced as a substitute for the development of drugs for treating cancer, cardiovascular diseases, neurodegenerative disorders, and various infectious diseases like Covid-19. Although the earlier lines of findings in this area were serendipitous, recent advancements are based on patient centered approaches following systematic, translational, drug targeting practices that explore pathophysiological ailment mechanisms. The presence of definite information and numerous records with respect to beneficial properties, harmfulness, and pharmacologic characteristics of repurposed drugs increase the chances of approval in the clinical trial stages. The last few years have showcased the successful emergence of repurposed drug immunotherapy in treating various diseases. In this light, the present review emphasises on incorporation of drug repositioning with Immunotherapy targeted for several disorders.
药物重新利用，也称为药物重新定位，是指应用预先批准或先前评估过的具有潜在功能性治疗组合的药物，以治疗与其原始治疗适应症不同的各种疾病或病症。它已成为开发治疗癌症、心血管疾病、神经退行性疾病以及各种传染病（如新冠病毒-19）药物的替代方法。尽管该领域早期的研究结果是偶然的，但最近的进展是基于以患者为中心的方法，遵循系统的、转化性的、药物靶向实践，探索病理生理疾病机制。关于重新利用药物的有益特性、有害性和药理学特征的确切信息和大量记录的存在，增加了在临床试验阶段获得批准的机会。过去几年展示了重新利用药物免疫疗法在治疗各种疾病方面的成功出现。有鉴于此，本综述着重探讨将药物重新定位与针对多种疾病的免疫疗法相结合。
